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Abstract
Objective To compare accuracy measures for mammographic
screening in Norway, Spain, and the US.
Methods Information from women aged 50–69 years who
underwent mammographic screening 1996–2009 in the US
(898,418 women), Norway (527,464), and Spain (517,317)
was included. Screen-detected cancer, interval cancer,
and the false-positive rates, sensitivity, specificity, posi-
tive predictive value (PPV) for recalls (PPV-1), PPV for
biopsies (PPV-2), 1/PPV-1 and 1/PPV-2 were computed
for each country. Analyses were stratified by age,
screening history, time since last screening, calendar
year, and mammography modality.
Results The rate of screen-detected cancers was 4.5, 5.5, and
4.0 per 1000 screening exams in the US, Norway, and Spain
respectively. The highest sensitivity and lowest specificity
were reported in the US (83.1 % and 91.3 %, respectively),
followed by Spain (79.0 % and 96.2 %) and Norway (75.5 %
and 97.1 %). In Norway, Spain and the US, PPV-1 was
16.4 %, 9.8 %, and 4.9 %, and PPV-2 was 39.4 %, 38.9 %,
and 25.9 %, respectively. The number of women needed to
recall to detect one cancer was 20.3, 6.1, and 10.2 in the US,
Norway, and Spain, respectively.
Conclusions Differences were found across countries, sug-
gesting that opportunistic screening may translate into higher
sensitivity at the cost of lower specificity and PPV.
Key Points
• Positive predictive value is higher in population-based
screening programmes in Spain and Norway.
• Opportunistic mammography screening in the US has lower
positive predictive value.
• Screening settings in the US translate into higher sensitivity
and lower specificity.
• The clinical burden may be higher for women screened
opportunistically.
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including invasive procedures
or (in the BCSC) recommendation
for invasive procedures.
BCSC Breast Cancer Surveillance
Consortium
SFM Screen-film mammography.
FFDM Full-field digital mammography.
BI-RADS Breast Imaging Reporting and
Data System
CAD Computer-aided detection.
CFPR Cumulative false-positive risk
SEER Surveillance, epidemiology, and
end results
FNAC Fine-needle aspiration cytology
DCIS Ductal carcinoma in situ
CI Confidence interval
Introduction
Over the last 20 years, mammographic screening has become
widespread in most developed countries, with the aim of re-
ducing breast cancer mortality through early detection of the
disease. However, the organisation and delivery vary across
geographic regions in ways that may influence its effective-
ness. Most countries in Europe offer population-based screen-
ing programmes following the recommendations of the Euro-
pean guidelines with defined screening intervals and target
populations related to age [1]. In the U.S, although several
organisations recommend routine screening [2, 3], actual
screening practices vary by personal and medical provider
preferences. Access to care also varies, for instance, by insur-
ance status. Most commonly, screening is opportunistic in
response to recommendations made during a routine medical
consultation or on the basis of a possible increased risk of
developing breast cancer [2].
Comparing accuracy measures across different
organisational models for mammographic screening provides
valuable information that can be used to guide clinical practice
and breast cancer screening policy. Only a few studies have
compared such measures across organisational models for
breast cancer screening and most have focused on the sensi-
tivity, specificity, and cancer rates [4–8]. Positive predictive
value (PPV), the proportion of women either recalled or who
undergo a biopsy and are subsequently diagnosed with cancer,
is reported less often.
This study utilises data collected in Norway and Spain as
part of the service screening programmes and in the US by the
Breast Cancer Surveillance Consortium (BCSC), a large on-
going study of mammographic screening performance in
community practice. We estimated accuracy measures for
mammographic screening in the three countries with the aim
of comparing the sensitivity and specificity as well as PPV.
Materials and methods
Information from 898,418 screened women in the US (1996–
2008), 527,464 in Norway (1996–2007), and 517,317 in
Spain (1996–2009) was included in the study. All women
were aged 50 to 69 years at screening. These women contrib-
uted a total of 5,713,594 screening exams.
Screening organisation
No organised mammography screening programme exists in
the US (Table 1). Screening is performed opportunistically,
typically according to the guidelines of organisations such as
the American Cancer Society [3] and the US Preventive Ser-
vices Task Force [2]. Under the Patient Protection and Afford-
able Care Act, all health insurance plans must cover screening
mammography with no patient cost sharing [9]. All facilities
performing screening mammography are accredited by the US
FDA and follow the regulations set forth by the Mammogra-
phy Quality Standards Act [10]. Recommendations generally
call for initiation of screening at age 40 or 50 and continuation
until at least age 74 [2]. The recommended screening interval
also varies, with some organisations calling for annual and
others for biennial screening. In consultation with their med-
ical providers, women choose to receive screening mammog-
raphy according to personal preference. Screening mammog-
raphy typically consists of two-view (mediolateral oblique
and craniocaudal views) bilateral examinations. Radiologists’
assessments and recommendations are based on the American
College of Radiology’s Breast Imaging Reporting and Data
System (BI-RADS®) [11] and are typically read by an indi-
vidual radiologist, sometimes with the use of computer-aided
detection (CAD). Full-field digital mammography (FFDM)
began diffusing into community practice after FDA approval
of the first FFDM machines in 2000. As of December 2009,
60 % of accredited mammography facilities in the US were
using FFDM [12].
Both Norway and Spain adhere to the European Guidelines
for Quality Assurance in Mammographic Screening [1] ,
which recommend biennial invitation to mammography
screening for women aged 50 to 69 years.
The Norwegian Breast Cancer Screening Programme is
administered by the Cancer Registry of Norway, which is also
responsible for the surveillance and quality assurance of the
programme. The Programme started in 1996 and became na-
tionwide in 2005. The participation rate was 76.2 % [13].
Women are invited to two-view bilateral mammography by
a personal invitation letter, regardless of cancer history. Wom-
en are screened at stationary and mobile units. The pro-
gramme performs independent reading with consensus/arbi-
tration. A score of 1–5 is given for each breast, by each radi-
ologist, where 1 indicates a negative screening examination
and 5 a high likelihood of malignancy. All cases with a score
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of 2 or higher given by one or both readers are discussed at a
consensus meeting where the final decision of whether to
recall the woman is made. Recall examinations take place at
one of the 16 screening centres. FFDM was implemented
gradually in Norway, from 2000v2011. As of the end of
2008, 48 % of the screening mammograms were performed
with FFDM [14].
The Spanish Breast Cancer Screening Programme started
in 1990 and was nationwide by 2006. The overall participa-
tion rate was 74.0 % [15]. In Spain, breast cancer screening is
government funded. Women are actively invited to participate
in population-based mammography screening by an invitation
letter. The standard procedure for radiological performance in
Spain is two-view mammography with double reading. The
BI-RADS® [11] scale or equivalent is used to rate the proba-
bility of cancer. Women with positive mammographic find-
ings, scored as 3, 4, 5, or 0, are recalled for further assessments
to confirm or rule out malignancy at reference hospitals of
each screening area. From 2004 onwards, FFDM was gradu-
ally introduced in Spain. As of December 2009, digital mam-
mograms represented 25.7 % of screening tests.
Data sources
The study is based on data from the BCSC in the US, the
Cancer Registry in Norway, and the updated database of the
Cumulative False Positive Risk (CFPR) study in Spain [16].
The BCSC is a consortium of breast imaging registries
throughout the US linked to population-based cancer regis-
tries. These registries collect information from community
mammography facilities on mammography examinations
and patient risk factors. The study included data on screening
examinations in 1996–2008 captured by seven regional regis-
tries from diverse geographic locations that have previously
been used to describe the distribution of screening mammog-
raphy accuracy in the US [17]. Subsequent breast cancer di-
agnoses were obtained by linking BCSC data to pathology
databases, regional Surveillance, Epidemiology, and End Re-
sults (SEER) programmes, and state tumour registries. Data
were pooled at a central Statistical Coordinating Center. Data
for this study were obtained from the BCSC Research Re-
source [18].
Screening data from Norway include examinations from
women screened throughout the country between 1996 and
2007. Data from screening in Spain were drawn from an
anonymised database that gathers information from eight
screening areas. The database was originally created in 2006
for the CFPR Study [16] and was subsequently updated [19,
20]. The study includes data from women screened between
1996 and 2009.
All BCSC registries and the BCSC Statistical Coordinating
Center received Institutional Review Board approval for ac-
tive or passive consenting processes or a waiver of consent to
enrol participants, link data, and perform analysis. All proce-
dures were Health Insurance Portability and Accountability
Act compliant, and registries and the Coordinating Center
received a Federal Certificate of Confidentiality and other
protections for the identities of women, physicians, and facil-
ities. Data collection in Norway followed the regulations of
the Cancer Registry of Norway and no ethical committee ap-
proval was necessary since all data received were aggregated.
Data collection in Spain was performed following a study
protocol approved by the institutional review boards at all
participating screening areas.
Definitions
For US women, a screening mammogram was defined as
bilateral mammograms with screening indication performed
onwomenwithout a personal history of breast cancer or breast
augmentation who had not receivedmammography within the
prior 9 months. In Norway and Spain, all mammograms per-
formed on women attending the population-based screening
programme were considered screening mammograms.
A recall was defined as abnormal findings on the screening
mammogram, leading to a recall for further assessment. Based
on the findings of the imaging workup, women were referred
back to screening or for an invasive procedure [fine-needle
Table 1 Description of the main characteristics of breast cancer screening organization in the US, Norway, and Spain
US Norway Spain




Target population 40 years and older 50-69 years 50-69 years
Screening interval 1-2 years 2 years 2 years




Double reading with consensus
or arbitration
Population coverage Vary by insurance status and
personal preference
100 % 100 %
CAD Computer-aided detection
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aspiration cytology (FNAC), core needle biopsy, or an open
biopsy]. Short-term follow-up at 6 months after the screening
examination is sometimes recommended in the US but is not
recommended in Spain and in Norway where further assess-
ment takes place and concludes within 4 months of the screen-
ing examination. For the BCSC cohort, a recall was defined as
a BI-RADS assessment of 0, 4, or 5 [11].
For all three countries a false-positive recall was defined as
a recall for further assessment where no breast cancer was
confirmed, regardless of the procedures performed. A false-
positive screening result may also include an invasive proce-
dure with benign morphology, referred to as a false positive
with invasive procedures. A screen-detected cancer was de-
fined as ductal carcinoma in situ (DCIS) or invasive breast
cancer diagnosed as a result of further assessment due to ab-
normal findings on the screening mammograms.
In the BCSC data, a positive screening result was defined
as false positive if no cancer was diagnosed within 12 months
of the screening examination and prior to the next screening
mammogram. All cancers diagnosed within 12 months of a
positive screening mammogram and prior to the next screen-
ing mammogram were considered screen-detected. An inter-
val cancer was defined as a breast cancer detected within
12 months after a negative screening mammogram and prior
to the next screening mammogram.
In Norway and Spain, false-positives and screen-detected
cancers were defined based on cancers diagnosed as a result of
further assessment conducted following the screening mam-
mogram. An interval cancer was defined as a breast cancer
diagnosed within 730 days after a negative screening exami-
nation, with or without an invasive procedure, and before the
next screening examination.
Sensitivity was defined as the number of screen-detected
cancers divided by the number of screen-detected cancers plus
interval cancers, while specificity was defined as the number
of true-negative screening examinations divided by the num-
ber of true-negatives tests plus false positives.
Rates were defined as the number of cases per 1000 screen-
ing examinations. PPV-1was defined as the number of screen-
detected breast cancers divided by the number of recalls due to
positive mammographic findings. PPV-2 refers to recalled ex-
aminations including invasive procedures or (in the BCSC)
recommendation for invasive procedures. The number of
women needed to be recalled and to undergo an invasive pro-
cedure to detect one breast cancer was estimated by taking the
inverse of PPV-1 (1/PPV-1) and PPV-2 (1/PPV-2),
respectively
Statistical analysis
We included all screening mammograms performed on eligi-
ble women during the study period, including multiple screen-
ing mammograms for some women. We used generalised
estimating equations (GEE) to account for within-woman cor-
relation by means of the robust Huber-White (sandwich) var-
iance estimator [21]. The z-test was used to examine differ-
ences in accuracy measures between countries. P-values<
0.05 were considered statistically significant.
Estimates of sensitivity and specificity were stratified by
several factors: first or subsequent screen, calendar year of the
screening mammogram, age at screening, and screening mo-
dality [screen-film mammography (SFM) or FFDM]. Cancer
detection rates, false-positive rates, PPV-1, and PPV-2 were
stratified by the time since the last screening mammogram
(<18 months, 18 to 30 months, >30 months). The 95 % con-
fidence intervals (95 % CIs) were calculated.
Analyses were conducted using R v.3.0.0 (US), STATA
v.12 (Spain), SPSS v.12.0 (Spain and Norway), and SAS
(Norway).
Results
The study included information about 5,713,594 screening
examinations from 1,943,199 women screened in 1996–
2009 at age 50 to 69 years. Overall, 26,430 cancers were
screen-detected and 6,756 emerged as interval cancers.
Tables 2 and 3 show overall measures of screening accura-
cy in the three countries. The highest rate of screen-detected
cancers was found in Norway, followed by the US and Spain
[5.5 cancers per 1,000 screening mammograms, 4.5‰ and
4.0‰, respectively (p<0.001)], which is equivalent to
181.5, 223.0, and 247.4 screening examinations needed to
detected one cancer, respectively. The highest rate of DCIS
was observed in the US, followed by Norway and Spain [1.1
‰, 0.9‰, and 0.7‰, respectively (p<0.001)]. The highest
sensitivity was reported in the US, followed by Spain and
Norway (83.1 %, 79.0 %, and 75.5 %). Conversely, the
highest specificity was found in Norway, followed by Spain
and the US (97.1 %, 96.2 %, and 91.3 %). PPV-1 was 16.4 %
inNorway, 9.8% in Spain, and 4.9% in the US, which implies
that 6.1 women were required to undergo further workup to
detect one cancer in Norway, 10.2 in Spain, and 20.3 in the
US. PPV-2 was 39.4 % in Norway, 38.9 % in Spain, and
25.9 % in the US.
Stratification revealed differences between the countries
for both sensitivity and specificity (Table 4) that were consis-
tent with the overall measures observed in Table 3. In all
strata, sensitivity was higher in the US than in Norway and
Spain, and specificity was lower in the US than in Norway and
Spain. However, there were some notable patterns in the dif-
ferences within specific strata. Specifically, differences in
specificity between countries were larger at the first compared
to subsequent screenings. The smallest differences for sensi-
tivity, but not for specificity, were detected in women aged
60–69 (83.8 %, 82.1 %, and 79.2 % in the US, Spain, and
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Norway, respectively). Differences in sensitivity among the
US, Norway, and Spain were greater with FFDM (85.8 %,
73.5 %, and 76.4 %, respectively). The only exception to this
pattern was found in the first years of the study period, where
the sensitivity in Spain was higher than in the US.
In both in Norway and Spain, the largest percentage
of subsequent examinations was performed 18–30
months after the prior examination (95.8 % and
93.9 %, respectively) whereas in the US 68.5 % of
screening tests were performed within 18 months of
the prior test (Table 5). For all countries, the longer
the time since the prior screening test, the higher the
rate of screen-detected cancers, invasive cancers, false-
positives, and PPV-1 was. PPV-1 for mammograms per-
formed 18–30 months after the last screening was
5.2 %, 19.4 %, and 11.6 % in the US, Norway, and
Spain, respectively.
Discussion
We compared accuracy measures for mammographic screen-
ing performed in community practice in the US and through
population-based screening programmes in two European
countries. The highest specificity and PPV were found in the
European population-based screening programmes, whereas
the highest sensitivity was found in the US. The results sug-
gest that the opportunistic approach with annual mammogra-
phy requires more interventions to detect one cancer com-
pared with biennial screening in organised programmes.
Opportunistic screening is known to be more intervention-
ist than population-based approaches, which translates into a
higher number of recalls and false-positive results, as reported
in prior studies comparing screening performance indicators
between the US and Europe [4, 7]. Different explanations for
the higher recall rates in the US have been proposed. First, the
Table 2 Number and rate (per 1000 screening examinations) of screen-detected, interval cancer and false-positive screening examinations (per 100
screening examinations) in mammographic screening performed in the US, Norway, and Spain
US Norway Spain
(1996–2008) n=2,656,834 n (rate) (1996–2007) 1,470,854 n (rate) (1996–2009) 1,585,906 n (rate)
Screen-detected cancers (n, rate per 1000 screening examinations)
All malignant lesions 11,916 (4.5‰) 8105 (5.5‰) 6409 (4.0‰)
Invasive 9028 (3.4‰) 6714 (4.6‰) 5147 (3.2‰)
DCIS 2888 (1.1‰) 1391 (0.9‰) 1077 (0.7‰)
Unknown 0 0 185 (0.1‰)
Interval cancers (n, rate per 1000 screening examinations)
All malignancies 2429 (0.9‰) 2623 (1.8‰) 1704 (1.1‰)
Invasive 2191 (0.8‰) 2485 (1.7‰) (NA)
DCIS 238 (0.1‰) 138 (0.1‰) (NA)
False-positive screening examinations (n, rate per 100 screening examinations)
Additional imaging 230,016 (8.7 %) 42,426 (2.9 %) 59,414 (3.7 %)
Invasive procedures 24,627 (0.9 %)a 12,476 (0.8 %) 10,229 (0.6 %)
aUS data do not capture all biopsies: the number of womenwhowere recommended to receive a biopsy, defined as BI-RADS assessment at the end of all
imaging workup of 4 or 5, or BI-RADS assessment of 0 or 3 accompanied by recommendation for biopsy, FNAC, or surgical consult is thus reported
Table 3 Sensitivity, specificity, positive predictive value of recalls (PPV-1) and invasive procedures (PPV-2) in mammographic screening performed
in the US, Norway, and Spain
US Norway Spain
(1996–2008) n =2,656,834 % (95 % CI) (1996–2007) 1,470,854 % (95 % CI) (1996–2009) 1,585,906 % (95 % CI)
Sensitivity 83.1 (82.4−83.7) 75.5 (74.7−76.4) 79.0 (78.1−79.9)
Specificity 91.3 (91.2−91.3) 97.1 (97.1−97.1) 96.2 (96.2−96.2)
PPV-1 4.9 (4.8−5.0) 16.4 (16.0−16.7) 9.8 (9.8−9.8)
1/PPV-1 20.3 (20.0−20.7) 6.1 (6.0−6.2) 10.2 (10.2−10.3)
PPV-2 25.9a (25.4−26.4) 39.4 (38.7−40.1) 38.9 (38.9−38.9)
1/PPV-2 3.9 (3.8−3.9) 2.5 ( 2.5−2.6) 2.6 (2.6−2.6)
a US data do not capture all biopsies: the number of womenwhowere recommended to receive a biopsy, defined as BI-RADS assessment at the end of all
imaging workup of 4 or 5, or BI-RADS assessment of 0 or 3 accompanied by recommendation for biopsy, FNAC, or surgical consult is thus reported
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use of a single reading and the lower radiologist interpretive
volume required in the US for accreditation may partially
explain the differences [12]. A minimum interpretive volume
of 5000 mammograms per radiologist per year is recommend-
ed in Europe [1]. These programmatic characteristics, howev-
er, have not been associated with a decrease in the sensitivity
or cancer detection rate [22]. A second explanation is that the
threat of lawsuits for malpractice in the US might induce ra-
diologists to order further tests and procedures aiming to de-
crease the number of missed cancers [23, 24]. Finally, differ-
ences exist with respect to the targets for recall rates: European
guidelines recommend <3% of mammograms should result in
recalls [1] while the BI-RADS recommendations in the US are
5-10 % [11]. In spite of organisational similarities between
Norway and Spain, we observed differences in PPV-1 as a
result of the higher detection rates and lower false-positive
rates in Norway than in Spain. The smaller cancer detection
rate observed in Spain can be partly attributed to the lower
background breast cancer incidence in this country in compar-
ison with Norway and the US [25]. Different definitions of
recall for invasive procedures among the US, Norway, and
Spainmay also partly explain the lower PPV-2 values reported
in the US.
The higher sensitivity in the US in comparison to
Norway and Spain can be partially explained by the
different screening periodicity. It could also be affected
by other factors such as the test sensitivity. However,
identifying the specific contributing factors is beyond
the scope of this study. Women in the US were less
likely to develop an interval cancer between screening
examinations, which were mostly annual, which was
directly reflected in sensitivity. Unfortunately, because
of differences in screening practices between the US
and the European screening programmes, we were not
able to compare the sensitivity for women screened ev-
ery 2 years in the three countries. Nevertheless, prior
work comparing the sensitivity between the US (based
on data from Vermont and North Carolina) and Norway
indicated that the sensitivity for 2-year screening inter-
vals in these US regions was almost the same as that in
Norway [4, 5, 8].
The trend of higher sensitivity and lower specificity in the
US vs. Spain and Norway persisted across all strata investi-
gated. Differences observed in first screenings, both for the
percentage of mammograms and for sensitivity and specifici-
ty, could be related to differences in recommendations for
screening initiation. In the US, some organisations and pro-
viders recommend that women begin screening at age 40 [3].
As a result, relatively few women have their initial screening
at age 50 or older. The comparison of characteristics of first
screening examinations is thus confounded by age at first
screening.
When comparing cancer rates among women who attended
screening with an 18-30-month interval, the values from the
US and Norway—countries with similar background breast
cancer incidence [25]—were similar. However, PPVs contin-
ued to differ. This reflects the fact that, while cancer detection
is mainly dependent on background incidence, PPV is more
sensitive to variations in radiological practice and the organi-
sation of the screening programme.
Our study has some limitations. First, we have taken a
descriptive approach based on aggregate data, and therefore
we did not control for potential confounders like individual
age. However, in an attempt to make data more comparable
across countries, we restricted the study population to women
aged 50–69. Second, despite using consensual definitions of
Table 5 Number and rates (per 1000 screening examinations) of screen-detected cancer, false-positive screening examinations (n, per 100 screening
examinations) and positive predictive value of recalls (PPV-1) and invasive procedures (PPV-2) by time since last screening examination
US Norway Spain
<18 months 18-30 months >30 months 18-30 months >30 months 18-30 months >30 months
(n=1,635,247) (n=496,738) (n=255,126) (n=903,709) (n=39,681) (n=1,003,210) (n=65,379)
Screen-detected cancers (n, rate per 1000 screening examinations)
All malignancies 5927 (3.6‰) 2363 (4.8‰) 1692 (6.6‰) 4486 (5.0‰) 311 (7.8‰) 3501 (3.5‰) 350 (5.4‰)
Invasive 4383 (2.7‰) 1814 (3.7‰) 1332 (5.2‰) 3723 (4.1‰) 265 (6.7‰) 2798 (2.8‰) 274 (4.2‰)
DCIS 1544 (0.9‰) 549 (1.1‰) 360 (1.4‰) 763 (0.8‰) 46 (1.2‰) 550 (0.5‰) 59 (0.9‰)
Unknown 0 0 0 0 0 153 (0.2‰) 17 (0.3‰)
False positives (n, rate per 100 screening examinations)
Additional images 124,896 (7.6 %) 42,644 (8.6 %) 26,784 (10.5 %) 19,068 (2.1 %) 1,181 (3.0 %) 26,731 (2.7 %) 2345 (3.6 %)
Invasive procedures 12,702 (0.8 %) 4220 (0.8 %) 3268 (1.3 %) 4805 (0.5 %) 387 (1.0 %) 3615 (0.4 %) 316 (0.5 %)
Positive predictive value (%, 95 % CI)
PPV-1 4.5 (4.4-4-6) 5.2 (5.0 - 5.4) 5.9 (5.6 - 6.2) 19.4 (18.9-19.9) 21.4 (19.4-23.6) 11.6 (11.6-11.6) 13.0 (13.0-13.0)
PPV-2 25.2 (24.5-25.8) 29.5 (28.4-30.7) 27.7 (26.5-29.0) 48.3 (47.3-49.3) 44.6 (47.3-49.3) 49.7 (49.7-49.7) 52.6 (52.5-52.5)
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the screening terms, some unavoidable differences remained
such as the definition for interval cancer in the US and Europe,
which directly affects the reported screening sensitivity.
In the US, estimates of sensitivity and/or interval can-
cers based on 2-year follow-up after the screening mam-
mogram would be biased because the majority of wom-
en return for another screening examination at a 1-year
interval. However, the results represent variability in the
radiological performance between countries, which is
the main objective of the study. Third, some overesti-
mation of sensitivity estimates in Spain cannot be
discounted since there is a lack of a nationwide cancer
registry, which may result in some missed interval can-
cers. However, the mechanisms for identifying interval
cancers have improved over time [26], which is
reflected in a decrease in sensitivity estimates.
In summary, the opportunistic approach to screening
in the US is more interventionist, resulting in more fre-
quent follow-up evaluations and shorter screening inter-
vals than the European population-based approaches.
This translates into a somewhat higher sensitivity of
screening mammography in the US but at the cost of
higher clinical burden on the women. Population-based
approaches stress the balance between sensitivity and
specificity, aiming to decrease the clinical burden—and
the related harms and costs—to participating women.
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